Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
PlexusDx's precision approach examines your individual GLP-1 receptor and metabolic gene variants alongside menopause physiology, enabling more informed conversations with your provider about whether semaglutide aligns with your specific hormonal and metabolic profile
If a pen has been frozen, discard it even if it has thawed, because freeze-thaw cycles can denature the protein 4
This is a series of Phase 3 trials studying retatrutide across multiple conditions: TRIUMPH-1 : Obesity (basket trial with nested OSA and OA protocols) TRIUMPH-2 : Obesity in type 2 diabetes population (with nested OSA) TRIUMPH-3 : Weight management in cardiovascular disease population TRIUMPH-4 : Obesity with knee osteoarthritis (completed results December 2025) Additional trials covering MASLD (metabolic dysfunction-associated steatotic liver disease), cardiovascular/renal outcomes, chronic low back pain, and weight maintenance TRANSCEND program: Dedicated type 2 diabetes trials (separate from TRIUMPH) TRIUMPH-4 was the first Phase 3 trial to report results, announced in December 2025
Reported injuries in GLP-1 lawsuits range from chronic nausea and vomiting to intestinal obstruction, malnutrition, emergency surgery, and sudden vision loss, with symptom severity typically ranging from temporary digestive complications to permanent impairment
US$ 21.25
US$ 26.79
US$ 23.02
US$ 23.80
US$ 23.31
US$ 21.90
